Table 1:
Patient demographic characteristics and tumor featuresa
| Study Group | Sample Size | Sex (Female/Male) | Age (yr) | Tumor Volume (cm3) | Tumor Stageb |
|||
|---|---|---|---|---|---|---|---|---|
| T1 | T2 | T3 | T4 | |||||
| IP training | 16 | 4:12 | 58.0 ± 12.1 | 21.2 ± 17.7 | 1 | 3 | 10 | 2 |
| IP validation | 6 | 1:5 | 58.2 ± 15.3 | 22.0 ± 6.9 | 1 | 1 | 3 | 1 |
| IP combined | 22 | 5:17c | 58.1 ± 13.1d | 21.4 ± 15.5e | 2 | 4 | 13 | 3 |
| SCC training | 17 | 4:13 | 54.0 ± 13.5 | 55.8 ± 40.5 | 0 | 1 | 4 | 12 |
| SCC validation | 7 | 1:6 | 54.6 ± 9.4 | 43.5 ± 27.9 | 0 | 1 | 2 | 4 |
| SCC combined | 24 | 5:19c | 54.2 ± 12.5d | 52.2 ± 37.7e | 0 | 2 | 6 | 16 |
a
Data are presented separately for the training and validation sets and also as a single combined cohort for each tumor type. Age and tumor volume are presented as means.
b
Tumor stage represents the Krouse staging system39 for IP and the American Joint Committee on Cancer staging40 for SCC.
c
Fisher exact test, P = .578.
d
Two-sample t test, P = .317.
e
Two-sample t test, P = .001.